We've got news for you.

Register on BusinessLIVE at no cost to receive newsletters, read exclusive articles & more.
Register now
European regulators have cleared Novavax’s vaccine, giving countries another tool against Covid-19. Picture: BLOOMBERG
European regulators have cleared Novavax’s vaccine, giving countries another tool against Covid-19. Picture: BLOOMBERG

Novavax’s vaccine was cleared by European regulators and is set to become the first Covid-19 shot of its kind in the region, giving countries another tool against Covid-19.

The protein-based shot, Nuvaxovid, was recommended by the European Medicines Agency, according to a statement on Monday. A European Commission decision authorising the vaccine is expected imminently.

The move follows a decision last week by the World Health Organisation granting the vaccine emergency-use status. It is a boost for Novavax, which has suffered months of delays after manufacturing problems despite securing some of the largest funding from the Trump administration in the early stages of the pandemic. The lag in the development of the shot compared with rivals such as Pfizer and Moderna hit its stock hard in recent months.

Novavax rose as much as 8.8% to $236.50 in early New York trading on Monday.

Results from two main clinical trials involving more than 45,000 people show the shot was effective at preventing Covid-19. The first study in Mexico and the US found a 90.4% reduction in the number of symptomatic Covid-19 cases from seven days after the second dose, compared with people given a placebo. The second study in the UK showed efficacy was similar at 89.7%.

There is limited data on the effectiveness of Nuvaxovid against Omicron, according to the European regulator. 

The Maryland-based company’s vaccine mimics the coronavirus’s spike protein, sparking an immune response that prepares the body for a real infection. The vaccine can be stored at refrigerator temperatures, making it easier to transport than some messenger-RNA shots.

The vaccine also shows strong potential in mix-and-match booster campaigns, relying on an approach that has been used for many years in vaccines against hepatitis, meningitis and other diseases, according to the vaccine alliance, Gavi. 

It also broadens Europe’s arsenal as the virus continues to spread. Novavax and the European Commission announced a supply agreement for as many as 200-million doses of the vaccine in August.

“An authorisation from the commission would deliver the first protein-based vaccine to the EU during a critical time when we believe having choice among vaccines will lead to increased immunisation,” Stanley Erck, Novavax’s CEO, wrote in the statement.

Bloomberg News. More stories like this are available on bloomberg.com


Would you like to comment on this article or view other readers' comments?
Register (it’s quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.